Literature DB >> 19826245

Prognostic factors in idiopathic pulmonary fibrosis.

Vasilios Tzilas1, Aspasia Koti, Dimitra Papandrinopoulou, Georgios Tsoukalas.   

Abstract

Idiopathic pulmonary fibrosis, 1 of the 7 idiopathic interstitial pneumonias, carries an ominous prognosis. It has a median survival of 2.8 years. However, there is significant heterogeneity in the actual length of survival, which varies from months to >5 years. Unfortunately, in addition to lung transplantation, no known medical intervention alters the natural history of the disease. Currently, many phase-III clinical trials are ongoing, but there is no Federal Drug Administration approved therapy. Thus, it is important for the clinician to be able to evaluate prognostic factors. These will help him draw conclusions about the possible course of his idiopathic pulmonary fibrosis patients and make important therapeutic decisions (lung transplantation).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19826245     DOI: 10.1097/MAJ.0b013e3181ad5984

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  7 in total

1.  A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis.

Authors:  Sameer R Oak; Lynne Murray; Athula Herath; Matthew Sleeman; Ian Anderson; Amrita D Joshi; Ana Lucia Coelho; Kevin R Flaherty; Galen B Toews; Darryl Knight; Fernando J Martinez; Cory M Hogaboam
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

2.  Relative Roles of TGF-β and IGFBP-5 in Idiopathic Pulmonary Fibrosis.

Authors:  A Sureshbabu; E Tonner; G J Allan; D J Flint
Journal:  Pulm Med       Date:  2011-01-26

3.  The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis.

Authors:  Ivana V Yang; Leah G Luna; Jennifer Cotter; Janet Talbert; Sonia M Leach; Raven Kidd; Julia Turner; Nathan Kummer; Dolly Kervitsky; Kevin K Brown; Kathy Boon; Marvin I Schwarz; David A Schwartz; Mark P Steele
Journal:  PLoS One       Date:  2012-06-22       Impact factor: 3.240

4.  Modulation of bleomycin-induced lung fibrosis by pegylated hyaluronidase and dopamine receptor antagonist in mice.

Authors:  Evgenii Germanovich Skurikhin; Olga Victorovna Pershina; Alena Mikhaylovna Reztsova; Natalia Nikolaevna Ermakova; Ekaterina Sergeevna Khmelevskaya; Vycheslav Andreevich Krupin; Inna Ernestovna Stepanova; Andrew Vladimirovich Artamonov; Andrew Alexandrovich Bekarev; Pavel Gennadjevich Madonov; Alexander Mikhaylovich Dygai
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

5.  Content validity of CASA-Q cough domains and UCSD-SOBQ for use in patients with Idiopathic Pulmonary Fibrosis.

Authors:  Katharine Suzanne Gries; Dirk Esser; Ingela Wiklund
Journal:  Glob J Health Sci       Date:  2013-09-16

6.  In vivo therapeutic success of MicroRNA-155 antagomir in a mouse model of pulmonary fibrosis induced by bleomycin.

Authors:  Xiaoyuan Sun; Yu Kang; Shan Xue; Jing Zou; Jiabo Xu; Daoqiang Tang; Hui Qin
Journal:  Korean J Intern Med       Date:  2020-06-09       Impact factor: 2.884

7.  Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency.

Authors:  Sven Gläser; Anne Obst; Beate Koch; Beate Henkel; Anita Grieger; Stephan B Felix; Michael Halank; Leonhard Bruch; Tom Bollmann; Christian Warnke; Christoph Schäper; Ralf Ewert
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.